Nicholas R Lemoine
Overview
Explore the profile of Nicholas R Lemoine including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
104
Citations
3805
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chen L, Wang P, Di Gioia C, Yuan M, Zhang Z, Miao J, et al.
Front Immunol
. 2025 Jan;
15():1492464.
PMID: 39840061
Oncolytic vaccinia viruses (VVs) are potent stimulators of the immune system and induce immune-mediated tumor clearance and long-term surveillance against tumor recurrence. As such they are ideal treatment modalities for...
2.
Xuan Y, Yan W, Wang R, Wang X, Guo Y, Dun H, et al.
Front Immunol
. 2025 Jan;
15():1506632.
PMID: 39830516
Pancreatic cancer is one of the most aggressive cancers and poses significant challenges to current therapies because of its complex immunosuppressive tumor microenvironment (TME). Oncolytic viruses armed with immunoregulatory molecules...
3.
Jiang G, Wang Z, Cheng Z, Wang W, Lu S, Zhang Z, et al.
Nat Commun
. 2024 Oct;
15(1):8988.
PMID: 39419971
Esophageal squamous cell carcinoma (ESCC) is highly heterogeneous. Our understanding of full molecular and immune landscape of ESCC remains limited, hindering the development of personalised therapeutic strategies. To address this,...
4.
Xu L, Sun H, Lemoine N, Xuan Y, Wang P
Front Immunol
. 2024 Jan;
14:1324744.
PMID: 38283361
Oncolytic virotherapy (OVT) is a promising form of cancer treatment that uses genetically engineered viruses to replicate within cancer cells and trigger anti-tumor immune response. In addition to killing cancer...
5.
Yan W, Chard Dunmall L, Lemoine N, Wang Y, Wang Y, Wang P
Front Immunol
. 2023 Dec;
14:1285801.
PMID: 38077392
γδ T cells, a specialized subset of T lymphocytes, have garnered significant attention within the realm of cancer immunotherapy. Operating at the nexus between adaptive and innate immunological paradigms, these...
6.
Zhou W, Miao J, Cheng Z, Wang Z, Wang J, Guo H, et al.
Mol Ther Oncolytics
. 2023 Sep;
30:216-226.
PMID: 37663131
CD19-targeted chimeric antigen receptor-modified T (CD19 CAR-T) cell therapy has been demonstrated as one of the most promising therapeutic strategies for treating B cell malignancies. However, it has shown limited...
7.
Wang L, Wang X, Wu Y, Wang J, Zhou W, Wang J, et al.
Cancer Lett
. 2023 Jul;
568:216303.
PMID: 37422126
Chimeric antigen receptor T cell immunotherapy has achieved promising therapeutic effects in the treatment of hematological malignancies. However, there are still many obstacles, including on-target off-tumor antigen expression, that prevent...
8.
Jia Y, Wang Y, Chard Dunmall L, Lemoine N, Wang P, Wang Y
Front Immunol
. 2023 Mar;
14:1126969.
PMID: 36923404
Cancer immunotherapy (CIT) has emerged as an exciting new pillar of cancer treatment. Although benefits have been achieved in individual patients, the overall response rate is still not satisfactory. To...
9.
Wong H, Jiang G, Gangeswaran R, Wang P, Wang J, Yuan M, et al.
Mol Ther
. 2022 Dec;
31(1):300.
PMID: 36476265
No abstract available.
10.
Sun Y, Zhang Z, Zhang C, Zhang N, Wang P, Chu Y, et al.
Mol Ther Oncolytics
. 2022 Jul;
26:105-119.
PMID: 35795092
Glioblastoma (GBM) is the most common primary malignant tumor in the brain, accounting for 51.4% of all primary brain tumors. GBM has a highly immunosuppressive tumor microenvironment (TME) and, as...